Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Cheryl Black

Endocrinology, Diabetes & Metabolism Oklahoma City, OK Medical Doctor

NPI 1447322680 CMS profile 155886

5401 N Portland, Ste 310, Oklahoma City, OK 73112

Open in the dashboard

General payments

$8,462

465 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Cheryl Black of Oklahoma City, OK is reported in the CMS Open Payments database as having received $8,462 across 465 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $169 10
2022 General $1,771 97
2021 General $1,960 126
2020 General $1,482 94
2019 General $3,080 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cheryl Black
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Cheryl Black were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Cheryl Black Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $3,080 $494 $123–$2,253 $163
2020 $1,482 $335 $85–$1,841 $114
2021 $1,960 $398 $88–$1,981 $132
2022 $1,771 $364 $88–$1,568 $149
2023 $169 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Medtronic MiniMed, Inc. $1,127 16 payments
  2. Novo Nordisk Inc $851 52 payments
  3. Amgen Inc. $848 55 payments
  4. AstraZeneca Pharmaceuticals LP $727 40 payments
  5. Abbott Laboratories $618 28 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $562 38 payments
  7. Lilly USA, LLC $459 28 payments
  8. Corcept Therapeutics $410 21 payments
  9. Tandem Diabetes Care, Inc. $375 21 payments
  10. Mannkind Corporation $349 23 payments
  11. Other $2,135 143 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,580 460 payments
  2. Travel and Lodging $883 5 payments
Products named General payments · program years 2019–2023
  1. Minimed 670G System $1,021 15 payments
  2. Ozempic $792 47 payments
  3. FARXIGA $698 39 payments
  4. Repatha $627 41 payments
  5. RYBELSUS $563 34 payments
  6. JARDIANCE $562 38 payments
  7. Korlym $410 21 payments
  8. FreeStyle Libre 2 $379 14 payments
  9. AFREZZA $349 23 payments
  10. GVOKE PFS $264 18 payments
  11. Other $4,281 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

465 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record